Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have received a consensus recommendation of “Moderate Buy” from the twenty-six ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, nineteen have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $890.60.

REGN has been the subject of several research reports. UBS Group reduced their price objective on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. Royal Bank of Canada dropped their price target on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating for the company in a research report on Wednesday, April 30th. Bank of America decreased their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th.

Regeneron Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ REGN opened at $594.32 on Friday. The stock has a market capitalization of $64.17 billion, a price-to-earnings ratio of 15.53, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals has a 52 week low of $520.50 and a 52 week high of $1,211.20. The firm has a 50-day moving average price of $599.96 and a 200 day moving average price of $682.98. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the business posted $9.55 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.59%. Regeneron Pharmaceuticals’s payout ratio is currently 8.96%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Capital International Investors grew its stake in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after buying an additional 1,390,534 shares during the period. Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $802,036,000. GAMMA Investing LLC grew its position in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after acquiring an additional 810,144 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $343,764,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.